Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic i-131 scans

Clinical Nuclear Medicine

Volumn 34, Issue 1, 2009, Pages 11-14

  Ömür, Özgür ^a   Akgün, Ayşegül ^a   Özcan, Zehra ^a   Şen, Çiǧdem ^a   Özklç, Hayal ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Diffuse liver uptake; Radioiodine; Thyroid carcinoma; Wholebody scan

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IODINE 131; LIVER ENZYME; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; DRUG UPTAKE; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID GLAND; WHOLE BODY RADIATION; ABLATION TECHNIQUE; DIFFUSION; FOLLOW UP; LABORATORY; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

ABLATION TECHNIQUES; DIFFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LABORATORIES; LIVER; MALE; MIDDLE AGED; THYROID NEOPLASMS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 59649111619     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31818f433c     Document Type: Article

References (16)

1. McDougall IR. Whole body scintigraphy withradioiodine-131 a comprehensive list of false-positives with some examples. Clin NuclMed. 1995;20:869.
2. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191.
3. Maayan MI, Eisenberg J, Lopez EM, et al. Hepatic visualization after 131-I in patients with thyroid carcinoma. N Engl J Med. 1977;295:1258.
4. Zeissman HA, Bahar H, Fahey FH, et al. Hepatic visualization on iodine-131 whole body thyroid cancer scans. J Nucl Med. 1987;28:1408-1411.
5. Tatar FA, Morita E, Ituarte PH, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of I-131 following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718-722.
6. Blum M. Hepatic visualization after 131-I in patients with thyroid carcinoma [letter]. N Engl J Med. 1977;296:634.
7. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657-660.
8. Carlisle MR, Lu C, McDougall IR. The interpretation of 131-I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24:715-735.
9. Albert DM, Puliafito CA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma [letter]. N Engl J Med. 1977;296:634.
10. Chapman EM, Maloof F. The use of radioiodine in the diagnosis and treatment of hyperthyroidism: ten years experience. Medicine. 1955;34:261-321.
11. Pochin EE. Profile counting: medical radioisotope scanning. Proc. of Semin IAEA and WHO. Vienna. Int Atom Energy Agency. 1959;143-162.
12. Bucker-Davis F, Reynolds JC, Skarulis MC, et al. False-positive iodine-131 whole-body scans due to cholecystitis and sebaceous cyst. J Nucl Med. 1996;37:1690-1693.
13. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implication. Eur J Endocrinol. 2006;155: 465-512.
14. - symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol. 1999;141:382-386.
15. Spitzweg C, Joba W, Schriever K, et al. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999;84:4178-4184.
16. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880-1888.